Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 30, Number 1—January 2024
Research

Molecular Evolution and Increasing Macrolide Resistance of Bordetella pertussis, Shanghai, China, 2016–2022

On This Page
Methods
Results
Discussion
Cite This Article
Figures
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Tables
Table
Downloads
Article
Appendix 1
Appendix 2
RIS [TXT - 2 KB]
Article Metrics
Metric Details
Related Articles
KPC-producing Klebsiella pneumoniae
CC398 MRSA Producing PVL, Czech Republic, 2023
Vancomycin-Resistant Staphylococcus aureus CC45/USA600, North Carolina, 2021
More articles on Antimicrobial Resistance
Author affiliations: National Children's Medical Center, Shanghai, China (P. Fu, J. Zhou, Y. Nijiati, L. Zhou, G. Yan, G. Lu, X. Zhai, C. Wang); Chinese Academy of Sciences, Shanghai (C. Yang)

Cite This Article

Abstract

Resurgence and spread of macrolide-resistant Bordetella pertussis (MRBP) threaten global public health. We collected 283 B. pertussis isolates during 2016–2022 in Shanghai, China, and conducted 23S rRNA gene A2047G mutation detection, multilocus variable-number tandem-repeat analysis, and virulence genotyping analysis. We performed whole-genome sequencing on representative strains. We detected pertussis primarily in infants (0–1 years of age) before 2020 and older children (>5–10 years of age) after 2020. The major genotypes were ptxP1/prn1/fhaB3/ptxA1/ptxC1/fim2–1/fim3–1 (48.7%) and ptxP3/prn2/fhaB1/ptxA1/ptxC2/fim2-1/fim3-1 (47.7%). MRBP increased remarkably from 2016 (36.4%) to 2022 (97.2%). All MRBPs before 2020 harbored ptxP1, and 51.4% belonged to multilocus variable-number tandem-repeat analysis type (MT) 195, whereas ptxP3-MRBP increased from 0% before 2020 to 66.7% after 2020, and all belonged to MT28. MT28 ptxP3-MRBP emerged only after 2020 and replaced the resident MT195 ptxP1-MRBP, revealing that 2020 was a watershed in the transformation of MRBP.

Whooping cough (pertussis) is a contagious respiratory illness caused by Bordetella pertussis. The introduction of the whole-cell vaccine (WCV) successfully decreased the incidence of pertussis. Although vaccination has been successful, replacement of the WCV with an acellular vaccine (ACV) has correlated with reemergence of pertussis, especially in adolescents and infants (1). In China, ACV was developed in the late 1990s and has replaced WCV and been exclusively used in China since 2012 (2,3). However, a multicenter study showed that the levels of protective antibodies against pertussis were already very low in immunized children 2–20 years of age (4).

Resurgence of pertussis has been widely reported and is mainly found in age groups of unvaccinated or incompletely vaccinated children or those whose immunity has waned (5,6). Mooi et al. (7,8) first identified the antigenic divergence between circulating isolates and vaccine strains in 1998, which explained the reemergence of pertussis and the distinct epidemiology of pertussis in different regions. Since then, a series of studies have demonstrated antigenic changes in bacterial virulence genes that might compromise vaccine-mediated immunity against B. pertussis (9–11). Virulence antigens, such as filamentous hemagglutinin (FHA), pertactin (Prn), pertussis toxin (PT), fimbriae2 (Fim2), and fimbriae3 (Fim3), are the essential components of ACV (12). PT export genes are regulated by the ptx promoter (ptxP) and may be required for efficient translation of ptx mRNA in B. pertussis strains (13). The ptxP region include 2 major alleles ptxP1 and ptxP3, and ptxP3 produces more PT than the ptxP1 allele (14).

In many countries, circulating B. pertussis harbors different virulence genotypes compared with vaccine strains (15,16). Different alleles of ptxP, fhaB, ptxA, ptxC, fim2, and fim3 have been reported in many studies (6,17,18). Among those virulence-related genes, the ptxC alleles ptxC1 and ptxC2 have been described; those alleles differ at a single nucleotide, resulting in a silent mutation (19). Compared with the major ptxP1/fhaB1/prn1/ptxA2 genotype of vaccine strains, the ptxP3/fhaB3/prn2/ptxA1 genotype have emerged in the circulating B. pertussis population in China (6,20,21).

Despite the variation in virulence genotypes in circulating strains, different B. pertussis subtypes are prevalent in the world. The multilocus variable-number tandem-repeat analysis (MLVA) type (MT) 27 strain carrying the genotype of ptxP3/ptxA1/prn2/fm3–1 has become the predominant B. pertussis strain in many countries (22). However, MT27 has seldomly been reported in China, whereas the MT55, MT195, or MT104 strains harboring the ptxP1 allele have been reported to circulate in some regions of China (23,24). Macrolide-resistant B. pertussis (MRBP), which carries an A-to-G transition at nucleotide position 2047 (A2047G mutation) in a region critical for erythromycin binding, emerged in some countries, but was only frequently detected in China (15,16,25–27). MRBPs generally carry ptxP1 and fhaB3, but 2 novel MRBPs belonging to MT28 and MT27 carrying ptxP3 and fhaB1 were reported in mainland China (15,28).

Our recent study reported that MT28 ptxP3-MRBP has emerged and spread in Shanghai, China, during 2021–2022 (29). However, several urgent questions remain to be resolved. For example, was ptxP3-MT28 MRBP dominant in Shanghai in the long term, or did it emerge in 2021 and 2022? Why and when did ptxP3-MT28 MRBP emerge in Shanghai, and how did they evolve? To resolve those questions, we conducted further research during 2016–2022 to reveal the evolution of MRBP in Shanghai. We collected a total of 283 B. pertussis isolates during 2016–2022 in Shanghai and systematically analyzed the antimicrobial resistance and molecular evolution of those strains.

Methods

Enrollment of Case-Patients with B. pertussis Infection

We included in the study a total of 1,065 children admitted to the Children’s Hospital of Fudan University and diagnosed with pertussis during January 2016–October 2022, who had nasopharyngeal swab (NP) samples collected and delivered to the microbiology laboratory for B. pertussis culture, antimicrobial resistance testing, and PCR detection. We extracted DNA from NP samples and performed real-time PCR (LightCycler 480; Roche, https://www.roche.com) to detect nucleic acids according to the protocol of a pertussis bacteria nucleic acid detection kit based on the PCR-fluorescent probe method (Yilifang Biotechnology, http://www.yilifangbio.com). The laboratory testing results and data collection were based on electronic medical records during hospitalization or clinic visits, and all data analysis was anonymous. The study protocol was approved by the Ethics Committee of the Children’s Hospital of Fudan University (approval no. 2022-66).

PCR and Sequencing for 23S rRNA A2047G Mutation Detection and Virulence Genotyping Analysis

We obtained 692 B. pertussis strains in 2016 (11 strains), 2017 (177 strains), 2018 (165 strains), 2019 (169 strains), 2020 (1 strain), 2021 (30 strains), and 2022 (139 strains). Because very few strains were obtained from 2016, 2020, and 2021, we selected all 42 strains for this study. We chose other isolates by the systematic sampling method, yielding 50 strains in 2017, 45 strains in 2018, 74 strains in 2019, and 72 strains in 2022. We gave each strain a number and then chose it by a random method to ensure each strain had an equal chance of being chosen through the use of an unbiased selection method. We selected a total of 283 isolates for further analysis.

We prepared genomic DNA of B. pertussis isolates by using a QIAamp DNA Mini Kit (QIAGEN, https://www.qiagen.com). We performed PCR-based sequencing of the A2047G mutation as described in a previous study (30). We also performed PCR and sequencing of virulence-related genes (ptxP, ptxA, ptxC, prn, fim2, fim3) as previously described (6). By using a convention for fhaB allele naming that defined fhaB1 and fhaB2 alleles by the A2493C mutation and defined the novel fhaB3 allele by the C5330T mutation, as previously described (23,31), we identified fhaB alleles by detecting and sequencing these 2 mutations. The primers for fhaB-2493 were forward, 5′-GATGTAGGCAAGGTTTCCGC-3′, and reverse, 5′-CGCTCGACACATGCAGAC-3′; the primers for fhaB-5330 were forward, 5′-ATATCGACAACAAGCAGGCC-3′, and reverse, 5′-TTGACATAGCCGATACCGCT-3′. We retrieved reported DNA sequences from GenBank and analyzed them by using BLAST (https://blast.ncbi.nlm.nih.gov) to determine the allele of each virulence gene.

MLVA

We performed MLVA by following the procedures described by Schouls et al. (32). We amplified 5 loci (variable-number tandem-repeat [VNTR] 1, VNTR3a/VNTR3b, VNTR4, VNTR5, and VNTR6) by using PCR detection. We calculated the number of repeats at each VNTR locus from the DNA fragment length. We assigned an MT on the basis of the combination of repeat counts for VNTRs 1, 3a, 3b, 4, 5, and 6, as described in previous reports (15,32).

DNA Extraction and Whole-Genome Sequencing

We further subjected 4 representative BP strains, including 1 MT27 ptxP3 macrolide-sensitive B. pertussis (MSBP) (BP1-Shanghai-2016), 1 MT195 ptxP1-MRBP (BP7-Shanghai-2016), 1 MT28 ptxP3-MSBP (P20-Shanghai-2017), and 1 MT28 ptxP3-MRBP (P745-Shanghai-2022) to whole-genome sequencing (WGS) analysis. We extracted genomic DNA by using the sodium dodecyl sulphate method (33). We constructed libraries for single-molecule real-time sequencing with an insert size of 10 kb by using the SMRTbell Template Prep Kit 1.0 (PacBio, https://www.pacb.com). We generated sequencing libraries for the Illumina platform by using the NEBNext Ultra DNA Library Prep Kit for Illumina (New England BioLabs, https://www.neb.com). We sequenced the whole genomes by using the PacBio Sequel platform and Illumina NovaSeq PE150 at Beijing Novogene Bioinformatics Technology Co., Ltd (Beijing, China). We deposited the sequencing data into GenBank (accession nos. CP118023–6).

Public Genome Dataset

We included a total of 1,491 public genomes of B. pertussis strains from China (15,21,28) and global B. pertussis P strains in this study for comparison (Appendix 1 Table). We sequenced the public genomes for various purposes, and they covered 27 countries from 8 geographic areas (Appendix 1 Table). We downloaded raw short-read sequencing data from the National Center for Biotechnology Information Sequence Read Archive (https://www.ncbi.nlm.nih.gov/sra). We filtered sequencing reads by using Trimmomatic (34), and we performed de novo genome assembly of public data by using SPAdes (35) with default settings.

Single-Nucleotide Polymorphism Calling and Phylogenetic Analysis

We identified core-genome (regions present in >99% of isolates) single-nucleotide polymorphisms (SNPs), as previously described (36). In brief, we aligned the assemblies against the reference genome (GenBank accession no. NC_002929.2, Tohama I) by using MUMmer (37) to generate whole-genome alignment. We performed SNP calling by using SNP-Sites (38) on the basis of the alignment. We identified the repetitive regions of the reference genome by using Tandem repeats finder and self-aligning by blastn (https://blast.ncbi.nlm.nih.gov). We excluded SNPs located in repetitive regions from further analysis. We constructed a maximum-likelihood phylogenetic tree by using RAxML-NG (39) under the general time-reversible with gamma distribution model.

Statistical Analysis

We analyzed data by using the t test, χ2 test, or Fisher exact test, as appropriate. We performed all statistical analyses by using the SPSS Statistics 13.0 (IBM, https://www.ibm.com). We considered p<0.05 to be statistically significant.

Results

Clinical Characteristics of Children with BP Infection

Figure 1

Distributions of pertussis patients in different age groups, Shanghai, China, 2016–2022. Pertussis was primarily detected from infants (0–1 years of age) before 2020 but mostly from older children and adolescents (>5–10 years of age) after 2020.

Figure 1. Distributions of pertussis patients in different age groups, Shanghai, China, 2016–2022. Pertussis was primarily detected from infants (0–1 years of age) before 2020 but mostly from older children and adolescents...

A total of 1,065 children had pertussis diagnosed at the Children’s Hospital of Fudan University during January 2016–October 2022 (Appendix 2 Table 1). Of those, 65.0% (692) had culture-proven pertussis, and the others were culture-negative but verified by PCR or clinical symptoms. The case-patients were 470 girls (44.1%) and 595 boys (55.9%), and the average age was 2.6 years (range 23 days–11.5 years). Approximately 93.8% of the case-patients (999) had cough symptoms; average duration of cough was of 20.7 days (range 1–130 days). Most of the patients (75.5% [804]) were treated with antibiotics before sampling, among which macrolides were used in 60.1% (640) of patients. The age distributions of pertussis changed from 2016 to 2022; pertussis was detected primarily in infants (0–1 years of age) (84.7%–100%) before 2020 but was mostly detected in older children and adolescents (>5–10 years of age) (50.3%–56.8%) after 2020 (p<0.001) (Figure 1).

MLVA Types of B. pertussis strains

We identified 14 MLVA types in this study, and the major MLVA types were MT195 (26.9%), MT28 (26.1%), MT27 (20.8%), MT104 (13.4%), and MT55 (6.4%) (Appendix 2 Table 2). The other MLVA types were MT158 (1.1%), MT 16 (1.1%), MT29 (0.7%), MT114 (0.7%), MT30 (0.4%), MT32 (0.4%), untyped-1 (0.4%), untyped-2 (1.1%), and untyped-3 (0.4%).

Figure 2

Distributions of prevalent Bordetella pertussis subtypes over time (A) and by age group (B), Shanghai, China, 2016–2022. Fourteen MTs were identified in this study. MT27 was the major strain during 2016–2019, whereas MT28 isolates increased quickly during 2021–2022 (panel A). MT distributions in infants (0–1 years of age) and noninfants (>1–12 years of age) change substantially from 2016–2019 to 2021–2022 (panel B). MT, multilocus variable-number tandem-repeat analysis type.

Figure 2. Distributions of prevalent Bordetella pertussissubtypes over time (A) and by age group (B), Shanghai, China, 2016–2022. Fourteen MTs were identified in this study. MT27 was the major strain...

Only 1 strain was isolated in 2020, so we deleted the analysis of 2020. MT27 was the main subtype during 2016–2019 (29.1%–54.5%). However, MT28, which accounted for 0–4.1% before 2020, accounted for 40.0% in 2021 and 77.8% in 2022 (Figure 2, panel A).

We further analyzed the MT distributions in different age groups. MT28, which was seldomly detected in infants (3.6% [6/169]) and absent in noninfants (>1–12 years of age) (0% [0/11]) during 2016–2019, was predominantly isolated from all age groups during 2021–2022, accounting for 64.9% (24/37) in infants, and 66.7% (44/66) in noninfants (Figure 2, panel B).

Virulence Gene Alleles and Genotype Profiles of B. pertussis Strains

We identified 2 ptxP alleles; we identified ptxP1 in 49.8% and ptxP3 in 50.2% of B. pertussis strains. ptxP3, which accounted for only 37.2% before 2020, became the major allele (73.5%) after 2020. Moreover, we identified 4 types of prn (prn1, prn2, prn3, and prn9), 2 types of fhaB (fhaB1 and fhaB3), 3 types of ptxC (ptxC1, ptxC2, and ptxC3), 1 type of ptxA (ptxA1), 1 type of fim2 (fim2–1), and 3 types of fim3 (fim3–1, fim3–2, and fim3–4).

ptxP1 was mostly linked to prn1 and fhaB3, whereas ptxP3 linked closely to prn2 and fhaB1. The major genotypes were ptxP1/prn1/fhaB3/ptxC1/ptxA1/fim2–1/fim3–1 (48.7%) and ptxP3/prn2/fhaB1/ptxC2/ptxA1/fim2–1/fim3–1 (47.7%): the former included 7 subtypes (MT16, MT27, MT30, MT55, MT104, MT195, and untyped-3), and the latter involved 6 subtypes (MT27, MT28, MT32, MT114, MT158, and untyped-2). (Appendix 2 Table 3).

A2047G mutation and Antimicrobial-Resistance Profiles of B. pertussis Strains

B. pertussis was highly resistant to macrolides, and MRBP accounted for 72.4% (205/283) of strains (Table). A total of 97.2% of ptxP1/prn1/fhaB3-BP and 91.9% of MT28 ptxP3/prn2/fhaB1-BP belonged to MRBP, whereas all non-MT28 ptxP3/prn2/fhaB1-BP were MSBP.

We frequently detected the A2047G mutation in 205 B. pertussis strains (72.4%) that showed 100% resistance to erythromycin, azithromycin, and clarithromycin. The A2047G mutation accounted for 61.0% before 2020 and 93.1% after 2020. All MT195, MT55, and MT104 carried the A2047G mutation, but none of the MT27 acquired this mutation. A2047G mutation in MT28 increased from 0% before 2020 to 100% after 2020.

Figure 3

Changing macrolide resistance of circulating Bordetella pertussis strains, Shanghai, China, 2016–2022. A) ptxP3-strains showed very high resistance to macrolides after 2020. Resistance to macrolides was different in non-MT28 (0%) and MT28 (100%) isolates. B) Percentages of macrolide-sensitive BP, ptxP1-MRBP, and ptxP3-MRBP before and after 2020 show that ptxP1-MRBP strain was prevalent before 2020 but predominately ptxP3-MRBP spread after 2020. MRBP, macrolide-resistant Bordetella pertussis; MT, multilocus variable-number tandem-repeat analysis type.

Figure 3. Changing macrolide resistance of circulating Bordetella pertussis strains, Shanghai, China, 2016–2022. A) ptxP3-strains showed very high resistance to macrolides after 2020. Resistance to macrolides was different...

Figure 4

Minimum-spanning tree of 283 Bordetella pertussis MTs, Shanghai, China, 2016–2022. A) Virulence genotype profiles; B) A2047G mutations; C) pre-2020 versus post-2020. Circle sizes indicate the number of each MT. Differences in the length and thickness of the lines linking 2 circles indicate differences in the number of variable-number tandem repeats between the 2 linked MTs. MT, multilocus variable-number tandem repeat analysis type.

Figure 4. Minimum-spanning tree of 283 Bordetella pertussisMTs, Shanghai, China, 2016–2022. A) Virulence genotype profiles; B) A2047G mutations; C) pre-2020 versus post-2020. Circle sizes indicate the number of each MT....

MRBP increased from 36.4% in 2016 to 97.2% in 2022, including ptxP1-MRBP (48.4% [137/283]) and ptxP3-MRBP (24.0% [68/283]). Most (100% in 2016, 2018, and 2021; 94.3% in 2017; 98.0% in 2019; and 93.3% in 2022) of the ptxP1 strains belonged to MRBP. However, macrolide resistance in ptxP3 strains increased from 0% before 2020 to 70.6% in 2021 and 98.2% in 2022. Of note, macrolides resistance in MT28 ptxP3-strains switched from 0% before 2020 to 100% after 2020, whereas all non-MT28 ptxP3 isolates showed sensitivity to macrolides (Figure 3, panel A). ptxP1-MRBP was prevalent before 2020 (111 [61.7%]); of those 111 strains, of which 57 (51.4%) were MT195. ptxP3-MRBP, which was absent before 2020, increased to 66.7% after 2020, and all of them belonged to MT28 (Figure 3, panel B; Figure 4).

Combination of MLVA Types, Virulence Genotypes, and A2047G Mutations

MT195, MT55, and MT104 all carried ptxP1/prn1/fhaB3 and the A2047 mutation (Figure 4). As 2 closely related MLVA types, 98.3% of MT27-BP and 98.6% of MT28-BP carried the genotype of ptxP3/prn2/fhaB1. However, the A2047G mutation was highly detected in MT28 (91.9%) but absent (0%) in MT27 (Figure 4, panels A, B). MT195, MT27, and MT104 were the major subtypes before 2020, whereas MT28 emerged and spread quickly after 2020 (Figure 4, panel C).

WGS Analysis

Figure 5

Maximum-likelihood phylogenetic tree of 4 Shanghai, China, and 1,491 global Bordetella pertussis strains, by geographic area, 2016–2022. Red lines indicate Shanghai strains; bold indicates 2 MT28 strains. Black dot indicates MT28-MRBP (B19005) strain from Anhui Province, China. Arrow indicates reference strain Tohama I. Shanghai strains associated phylogenetic subclades are enlarged for visualization. MSBP, macrolide-sensitive Bordetella pertussis; MT, multilocus variable-number tandem-repeat analysis type; NA, not applicable.

Figure 5. Maximum-likelihood phylogenetic tree of 4 Shanghai, China, and 1,491 global Bordetella pertussisstrains, by geographic area, 2016–2022. Red lines indicate Shanghai strains; bold indicates 2 MT28 strains. Black dot...

Four B. pertussis strains (MT27 ptxP3-MSBP, MT195 ptxP1-MRBP, MT28 ptxP3-MSBP, and MT28 ptxP3-MRBP) were chosen for further WGS analysis. We constructed a maximum-likelihood phylogenetic tree of 4 Shanghai and 1,491 global strains. B. pertussis isolates in Shanghai were closely related to other isolates from China but differed from other international strains isolated from the United States, Europe, Australia, Argentina, Africa, Japan, Iran, Israel, and other regions and countries (Figure 5). Of note, MT28-MRBP (P745) was prevalent after 2020 and was closely related to MT28 ptxP3-MSBP (P20) but was quite heterogeneous to MT195-MRBP (BP7) and MT27 ptxP3-MSBP (BP1) before 2020. Moreover, P745 was highly homologous to a previously reported MT28-MRBP (B19005) in Anhui Province, China.

Discussion

In this study, we systematically investigated the clinical characteristics, antimicrobial resistance profiles, and molecular evolution of B. pertussis strains in Shanghai, China, during 2016–2022. Pertussis was primarily diagnosed in infants before 2020 but mostly in older children and adolescents after 2020. MRBPs remarkably increased, from 36.4% in 2016 to 97.2% in 2022. MT28 ptxP3/prn2/fhaB1-MRBP emerged only after 2020 and replaced MT195 ptxP1/prn1/fhaB3-MRBP, which was prevalent before 2020, indicating that 2020 was a watershed in the transformation of MRBP in Shanghai, China.

The first MRBP in China was reported in Shandong Province in 2011 (40). MRBPs in China was thought less likely to cause epidemics in other countries because the MRBPs in China were mostly assigned to ptxP1 lineage, whereas ptxP3 strains are currently endemic in other countries (21,27). In China, ptxP1-MRBPs were reported to contribute 75.4% (Zhejiang Province, 2016), 48.6% (Shenzhen Province, 2015–2017), and 84.9% (a multicenter study during 2017–2019) of the circulating B. pertussis strains in China (15,41,42). Previous studies showed that MRBP was mostly linked to the ptxP1 allele and that the ptxP3 strain was isolated from MSBP without exception (6,20,41). Our recent study demonstrated that the ptxP3 allele had a close linkage with MRBP (29). In this study, ptxP1-MRBP was the major (61.7%) strain during 2016–2020, whereas ptxP3-MRBP, which emerged only after 2020, replaced ptxP1-MRBP and became predominant (66.7%) after 2020.

MRBP strains were widely prevalent in western China and mainly linked to MT195, MT104, and MT55 (26). Wu et al. (15) showed that MT28 MRBP with genotype of ptxP3/fhaB1/prn9 was first identified in Anhui Province, China, revealing the emergence of ptxP3-MRBP in mainland China (15). In this study, the circulating B. pertussis strains changed greatly from 2016 to 2022. MT195 presented the VNTR profiles of 8-6-0-7-6-8, whereas MT28 showed the profiles of 8-7-0-7-6-8, and MT27 showed the profiles of 8-7-0-7-6-7. Although those subtypes have minor differences on VNTR3a or VNTR6, their virulence genotypes and A2047G mutation carriages were quite different, making the circulating strains very heterologous. All MRBPs before 2020 harbored ptxP1 and 51.4% belonged to MT195, whereas ptxP3-MRBP, which was absent before 2020, increased to 66.7% after 2020, and all belonged to MT28. WGS analysis further revealed that MT28-MRBP was quite heterologous with MT195-MRBP, revealing the different molecular characteristics of MRBP prevalent before and after 2020 in Shanghai.

MT28-MRBP in this study was quite different from the international strains but represented close relevance to MT28-MSBP isolated before 2020, which indicates that MT28-MRBP was not reported from other countries but more likely because the resident MT28-MSBP acquired the A2047G mutation and became resistant to macrolides. Moreover, the emergence and spread of MT28 ptxP3-MRBP in Shanghai were probably related to the selection pressure from high usage of macrolides and vaccination. Macrolides were excessively used for treating pertussis, which might participate in the selection of ptxP3-MRBP. Of interest, although MRBPs are highly resistant to macrolides, most (60.1%) of the MRBP patients were still treated with macrolides in this study. In addition, compared with vaccine strains in China with the genotype of ptxP1/fhaB1/prn1/ptxA2/ptxC1, MT28 harbored more gene variants, including ptxP3, prn2, ptxA1, and ptxC2 than MT195, which carried fhaB3 and ptxA1. Currently, 2 types of diphtheria, tetanus, and pertussis (DTaP) vaccine formulations are licensed in China: one is the 2-component DTaP vaccine containing PT and FHA, another is the 3-component DTaP vaccine containing PT, FHA, and PRN (43). The circulating B. pertussis has evolved, mainly changed from ptxP1 to ptxP3 lineage, indicating the ptxP3 variation reflect selective advantage under high coverage with acellular pertussis vaccine (42). Previous study showed that prn2 variation affected the efficacy of commercial vaccine, and mice studies suggested that the incorporation of prn2 to vaccine could enhance the ACV’s efficacy (44). Moreover, studies from Safarchi et al. (45) and Van Gent et al. (46) demonstrate that ptxP3/prn2-BP colonized better than the ptxP1/prn3-BP strain and provide the evidence for increased fitness and better immune evasion of ptxP3/prn2 strains in a mouse model involving mice immunized with 3-component ACVs. Therefore, we hypothesized that prn2 and ptxP3 variation in MT28 strains may play a role in better fitness and immune evasion compared with ACVs in China, causing MT28-BP to be selected by the vaccination and then to spread quickly. The exact relationship between prn2/ptxP3 variant and vaccine escape needs further study.

In this study, pertussis was primarily detected in infants before 2020 but was mostly detected in older children after 2020. We propose 2 potential hypotheses for this age shift. First, the age shift was closely related to the emergence of MT28-MRBP; ptxP3/ptxA1/ptxC2/prn2-carrying MT28 strains, which emerged and spread after 2020 could avoid the immunity of vaccine and weaken the vaccine effects, making the pertussis populations shift from unvaccinated or incompletely vaccinated infants to vaccinated population. Second, the COVID-19 pandemic increased the public awareness of microbiologic laboratory testing in children with respiratory symptoms, so more older children who were not considered as the primary pertussis population before 2020 accepted B. pertussis testing and were diagnosed with pertussis after 2020, making 2020 become the watershed moment for the shift of pertussis population.

In conclusion, we systematically investigated the molecular evolution of MRBPs to clarify the evolution of MRBP from MT195 to MT28 in Shanghai, China, during 2016–2022, revealing that 2020 was watershed in the transformation of MRBPs from MT195 ptxP1/prn1/fhaB3-alleles to MT28 ptxP3/prn2/fhaB1-alleles in Shanghai. The emergence and spread of MT28 ptxP3-MRBP strains are likely attributable to the A2047G mutation and the selection pressure from vaccination and high usage of macrolides, which will further complicate the epidemiology of pertussis and evolve to pose a looming threat to global public health. Therefore, worldwide surveillance of the molecular evolution and AMR profiles of circulating B. pertussis, especially ptxP3-MRBP, is urgent.

Dr. Fu is an associate professor at the Clinical Microbiology Laboratory at Children’s Hospital of Fudan University. Her primary research interests include pediatric infectious diseases and multidrug-resistant organisms. Dr. J. Zhou is a master candidate at Children’s Hospital of Fudan University. Her primary research interests include infectious diseases and organisms in pediatric ICU department.

Top

Acknowledgments

This study was funded by the National Key Research and Development Program of China (grant nos. 2021YFC2701800 and 2021YFC2701801), the Key Development Program of the Children’s Hospital at Fudan University (grant no. EK2022ZX05), and the National Natural Science Foundation of China (grant no. 82202567).

Author contribution: C.W., X.Z., and P.F. designed the experiments and revised the manuscript. C.Y. performed WGS analysis, analyzed the data, and revised the manuscript. P.F. analyzed the data and wrote the manuscript. J.Z. performed most of the experiments. G.L. performed experiments guidance. Y.N., G.Y., and L.Z. participated in the experiments.

Top

References

  1. Scheller  EV, Cotter  PA. Bordetella filamentous hemagglutinin and fimbriae: critical adhesins with unrealized vaccine potential. Pathog Dis. 2015;73:ftv079. DOIPubMedGoogle Scholar
  2. Xu  Y, Zhang  L, Tan  Y, Wang  L, Zhang  S, Wang  J. Genetic diversity and population dynamics of Bordetella pertussis in China between 1950-2007. Vaccine. 2015;33:6327–31. DOIPubMedGoogle Scholar
  3. Litt  DJ, Neal  SE, Fry  NK. Changes in genetic diversity of the Bordetella pertussis population in the United Kingdom between 1920 and 2006 reflect vaccination coverage and emergence of a single dominant clonal type. J Clin Microbiol. 2009;47:680–8. DOIPubMedGoogle Scholar
  4. Wang  CQ, Zhu  QR. Seroprevalence of Bordetella pertussis antibody in children and adolescents in China. Pediatr Infect Dis J. 2011;30:593–6. DOIPubMedGoogle Scholar
  5. Mooi  FR, Van Der Maas  NA, De Melker  HE. Pertussis resurgence: waning immunity and pathogen adaptation - two sides of the same coin. Epidemiol Infect. 2014;142:685–94. DOIPubMedGoogle Scholar
  6. Fu  P, Wang  C, Tian  H, Kang  Z, Zeng  M. Bordetella pertussis infection in infants and young children in Shanghai, China, 2016–2017: clinical features, genotype variations of antigenic genes and macrolides resistance. Pediatr Infect Dis J. 2019;38:370–6. DOIPubMedGoogle Scholar
  7. Mooi  FR, van Oirschot  H, Heuvelman  K, van der Heide  HG, Gaastra  W, Willems  RJ. Polymorphism in the Bordetella pertussis virulence factors P.69/pertactin and pertussis toxin in The Netherlands: temporal trends and evidence for vaccine-driven evolution. Infect Immun. 1998;66:670–5. DOIPubMedGoogle Scholar
  8. Mooi  FR, He  Q, van Oirschot  H, Mertsola  J. Variation in the Bordetella pertussis virulence factors pertussis toxin and pertactin in vaccine strains and clinical isolates in Finland. Infect Immun. 1999;67:3133–4. DOIPubMedGoogle Scholar
  9. Cassiday  P, Sanden  G, Heuvelman  K, Mooi  F, Bisgard  KM, Popovic  T. Polymorphism in Bordetella pertussis pertactin and pertussis toxin virulence factors in the United States, 1935-1999. J Infect Dis. 2000;182:1402–8. DOIPubMedGoogle Scholar
  10. Elomaa  A, Advani  A, Donnelly  D, Antila  M, Mertsola  J, Hallander  H, et al. Strain variation among Bordetella pertussis isolates in finland, where the whole-cell pertussis vaccine has been used for 50 years. J Clin Microbiol. 2005;43:3681–7. DOIPubMedGoogle Scholar
  11. Mastrantonio  P, Spigaglia  P, Oirschot  HV, van der Heide  HGJ, Heuvelman  K, Stefanelli  P, et al. Antigenic variants in Bordetella pertussis strains isolated from vaccinated and unvaccinated children. Microbiology (Reading). 1999;145:2069–75. DOIPubMedGoogle Scholar
  12. Guiso  N. Bordetella pertussis: why is it still circulating? J Infect. 2014;68(Suppl 1):S119–24. DOIPubMedGoogle Scholar
  13. Baker  SM, Masi  A, Liu  DF, Novitsky  BK, Deich  RA. Pertussis toxin export genes are regulated by the ptx promoter and may be required for efficient translation of ptx mRNA in Bordetella pertussis. Infect Immun. 1995;63:3920–6. DOIPubMedGoogle Scholar
  14. Mooi  FR, van Loo  IH, van Gent  M, He  Q, Bart  MJ, Heuvelman  KJ, et al. Bordetella pertussis strains with increased toxin production associated with pertussis resurgence. Emerg Infect Dis. 2009;15:1206–13. DOIPubMedGoogle Scholar
  15. Wu  X, Du  Q, Li  D, Yuan  L, Meng  Q, Fu  Z, et al. A cross-sectional study revealing the emergence of erythromycin-resistant Bordetella pertussis carrying ptxP3 alleles in China. Front Microbiol. 2022;13:901617. DOIPubMedGoogle Scholar
  16. Ivaska  L, Barkoff  AM, Mertsola  J, He  Q. Macrolide resistance in Bordetella pertussis: current situation and future challenges. Antibiotics (Basel). 2022;11:1570. DOIPubMedGoogle Scholar
  17. Moriuchi  T, Vichit  O, Vutthikol  Y, Hossain  MS, Samnang  C, Toda  K, et al. Molecular epidemiology of Bordetella pertussis in Cambodia determined by direct genotyping of clinical specimens. Int J Infect Dis. 2017;62:56–8. DOIPubMedGoogle Scholar
  18. Advani  A, Gustafsson  L, Ahrén  C, Mooi  FR, Hallander  HO. Appearance of Fim3 and ptxP3-Bordetella pertussis strains, in two regions of Sweden with different vaccination programs. Vaccine. 2011;29:3438–42. DOIPubMedGoogle Scholar
  19. van Loo  IHM, Mooi  FR. Changes in the Dutch Bordetella pertussis population in the first 20 years after the introduction of whole-cell vaccines. Microbiology (Reading). 2002;148:2011–8. DOIPubMedGoogle Scholar
  20. Yang  Y, Yao  K, Ma  X, Shi  W, Yuan  L, Yang  Y. Variation in Bordetella pertussis susceptibility to erythromycin and virulence-related genotype changes in China (1970–2014). PLoS One. 2015;10:e0138941. DOIPubMedGoogle Scholar
  21. Yao  K, Deng  J, Ma  X, Dai  W, Chen  Q, Zhou  K, et al. The epidemic of erythromycin-resistant Bordetella pertussis with limited genome variation associated with pertussis resurgence in China. Expert Rev Vaccines. 2020;19:1093–9. DOIPubMedGoogle Scholar
  22. Kamachi  K, Yao  SM, Chiang  CS, Koide  K, Otsuka  N, Shibayama  K. Rapid and simple SNP genotyping for Bordetella pertussis epidemic strain MT27 based on a multiplexed single-base extension assay. Sci Rep. 2021;11:4823. DOIPubMedGoogle Scholar
  23. Xu  Z, Wang  Z, Luan  Y, Li  Y, Liu  X, Peng  X, et al. Genomic epidemiology of erythromycin-resistant Bordetella pertussis in China. Emerg Microbes Infect. 2019;8:461–70. DOIPubMedGoogle Scholar
  24. Du  Q, Wang  X, Liu  Y, Luan  Y, Zhang  J, Li  Y, et al. Direct molecular typing of Bordetella pertussis from nasopharyngeal specimens in China in 2012-2013. Eur J Clin Microbiol Infect Dis. 2016;35:1211–4. DOIPubMedGoogle Scholar
  25. Wu  S, Hu  Q, Yang  C, Zhou  H, Chen  H, Zhang  Y, et al. Molecular epidemiology of Bordetella pertussis and analysis of vaccine antigen genes from clinical isolates from Shenzhen, China. Ann Clin Microbiol Antimicrob. 2021;20:53. DOIPubMedGoogle Scholar
  26. Zhang  J, Zhang  D, Wang  X, Wei  X, Li  H. Macrolide susceptibility and molecular characteristics of Bordetella pertussis. J Int Med Res. 2022;50:3000605221078782. DOIPubMedGoogle Scholar
  27. Feng  Y, Chiu  CH, Heininger  U, Hozbor  DF, Tan  TQ, von König  CW. Emerging macrolide resistance in Bordetella pertussis in mainland China: Findings and warning from the global pertussis initiative. Lancet Reg Health West Pac. 2021;8:100098. DOIPubMedGoogle Scholar
  28. Koide  K, Yao  S, Chiang  CS, Thuy  PTB, Nga  DTT, Huong  DT, et al. Genotyping and macrolide-resistant mutation of Bordetella pertussis in East and South-East Asia. J Glob Antimicrob Resist. 2022;31:263–9. DOIPubMedGoogle Scholar
  29. Fu  P, Zhou  J, Meng  J, Liu  Z, Nijiati  Y, He  L, et al. Emergence and spread of MT28 ptxP3 allele macrolide-resistant Bordetella pertussis from 2021 to 2022 in China. Int J Infect Dis. 2023;128:205–11. DOIPubMedGoogle Scholar
  30. Wang  Z, Cui  Z, Li  Y, Hou  T, Liu  X, Xi  Y, et al. High prevalence of erythromycin-resistant Bordetella pertussis in Xi’an, China. Clin Microbiol Infect. 2014;20:O825–30. DOIPubMedGoogle Scholar
  31. van Loo  IH, Heuvelman  KJ, King  AJ, Mooi  FR. Multilocus sequence typing of Bordetella pertussis based on surface protein genes. J Clin Microbiol. 2002;40:1994–2001. DOIPubMedGoogle Scholar
  32. Schouls  LM, van der Heide  HG, Vauterin  L, Vauterin  P, Mooi  FR. Multiple-locus variable-number tandem repeat analysis of Dutch Bordetella pertussis strains reveals rapid genetic changes with clonal expansion during the late 1990s. J Bacteriol. 2004;186:5496–505. DOIPubMedGoogle Scholar
  33. Lim  HJ, Lee  EH, Yoon  Y, Chua  B, Son  A. Portable lysis apparatus for rapid single-step DNA extraction of Bacillus subtilis. J Appl Microbiol. 2016;120:379–87. DOIPubMedGoogle Scholar
  34. Bolger  AM, Lohse  M, Usadel  B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics. 2014;30:2114–20. DOIPubMedGoogle Scholar
  35. Bankevich  A, Nurk  S, Antipov  D, Gurevich  AA, Dvorkin  M, Kulikov  AS, et al. SPAdes: a new genome assembly algorithm and its applications to single-cell sequencing. J Comput Biol. 2012;19:455–77. DOIPubMedGoogle Scholar
  36. Yang  C, Li  Y, Jiang  M, Wang  L, Jiang  Y, Hu  L, et al. Outbreak dynamics of foodborne pathogen Vibrio parahaemolyticus over a seventeen year period implies hidden reservoirs. Nat Microbiol. 2022;7:1221–9. DOIPubMedGoogle Scholar
  37. Delcher  AL, Salzberg  SL, Phillippy  AM. Using MUMmer to identify similar regions in large sequence sets. Curr Protoc Bioinformatics. 2003 Feb;Chapter 10:Unit 10.3.
  38. Page  AJ, Taylor  B, Delaney  AJ, Soares  J, Seemann  T, Keane  JA, et al. SNP-sites: rapid efficient extraction of SNPs from multi-FASTA alignments. Microb Genom. 2016;2:e000056. DOIPubMedGoogle Scholar
  39. Kozlov  AM, Darriba  D, Flouri  T, Morel  B, Stamatakis  A. RAxML-NG: a fast, scalable and user-friendly tool for maximum likelihood phylogenetic inference. Bioinformatics. 2019;35:4453–5. DOIPubMedGoogle Scholar
  40. Zhang  Q, Li  M, Wang  L, Xin  T, He  Q. High-resolution melting analysis for the detection of two erythromycin-resistant Bordetella pertussis strains carried by healthy schoolchildren in China. Clin Microbiol Infect. 2013;19:E260–2. DOIPubMedGoogle Scholar
  41. Zhang  JS, Wang  HM, Yao  KH, Liu  Y, Lei  YL, Deng  JK, et al. Clinical characteristics, molecular epidemiology and antimicrobial susceptibility of pertussis among children in southern China. World J Pediatr. 2020;16:185–92. DOIPubMedGoogle Scholar
  42. Wang  Z, Luan  Y, Du  Q, Shu  C, Peng  X, Wei  H, et al. The global prevalence ptxP3 lineage of Bordetella pertussis was rare in young children with the co-purified aPV vaccination: a 5 years retrospective study. BMC Infect Dis. 2020;20:615. DOIPubMedGoogle Scholar
  43. Wang  L, Lei  D, Zhang  S. Acellular pertussis vaccines in China. Vaccine. 2012;30:7174–8. DOIPubMedGoogle Scholar
  44. Quintana-Vázquez  D, Coizeau  E, Alvarez  A, Delgado  M, Cárdenas  T, Ramos  Y, et al. Recombinant hybrid proteins from pertactin type 1 and 2 of Bordetella pertussis are more immunogenic in mice than the original molecules. Biotecnol Apl. 2014;31:33–42.
  45. Safarchi  A, Octavia  S, Luu  LD, Tay  CY, Sintchenko  V, Wood  N, et al. Better colonisation of newly emerged Bordetella pertussis in the co-infection mouse model study. Vaccine. 2016;34:3967–71. DOIPubMedGoogle Scholar
  46. van Gent  M, van Loo  IH, Heuvelman  KJ, de Neeling  AJ, Teunis  P, Mooi  FR. Studies on Prn variation in the mouse model and comparison with epidemiological data. PLoS One. 2011;6:e18014. DOIPubMedGoogle Scholar

Top

Figures
Table

Top

Cite This Article

DOI: 10.3201/eid3001.221588

Original Publication Date: December 13, 2023

1These first authors contributed equally to this article.

Table of Contents – Volume 30, Number 1—January 2024

EID Search Options
presentation_01 Advanced Article Search – Search articles by author and/or keyword.
presentation_01 Articles by Country Search – Search articles by the topic country.
presentation_01 Article Type Search – Search articles by article type and issue.

Top

Comments

Please use the form below to submit correspondence to the authors or contact them at the following address:

Wang Chuanqing, Pan Fu, or Xiaowen Zhai, Children’s Hospital of Fudan University, 399 Wanyuan Rd, Shanghai 201102, China

Send To

10000 character(s) remaining.

Top

Page created: November 19, 2023
Page updated: December 20, 2023
Page reviewed: December 20, 2023
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external